Floatz Rating
B57/100
Confidence
Indicative
Sponsor
University of Turin, Italy
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm Of Thorax
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vinorelbine Ditartrate (this asset) | University of Turin, Italy | P3 | B · 57 |
| Carboplatin | Fundación GECP | P3 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Nanfang Hospital, Southern Medical University | P3 | B |
| Pembrolizumab | Amgen | P3 | B |
| Gefitinib | Chinese Society of Lung Cancer | P3 | B |
| Rivoceranib | Sichuan Cancer Hospital and Research Institute | P2 | B |
| L-Bupivacaine | Guy's and St Thomas' NHS Foundation Trust | P2/3 | B |
| Docetaxel | University of Turin, Italy | P3 | B |
+15 more in the Neoplasm Of Thorax cohort
Other indications for Vinorelbine Ditartrate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P3 | BBB · 72 |
| Cervical Cancer | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vinorelbine Ditartrate in Neoplasm Of Thorax. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vinorelbine-ditartrate-neoplasm-of-thorax
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →